Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMPT: PROCRIT Maintenance Dosing in CKD Anemia
NCT00307814Phase 2Completed
- Sponsor
- Ortho Biotech Inc.
- Start
- Jan 2002
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 2, randomised, open-label trial of epoetin alfa in anemia of chronic kidney disease (CKD-A) (4 arms), sponsored by Ortho Biotech Inc. Primary endpoints: Hemoglobin maintenance at 16 weeks, Incidence and severity of adverse events at 16 weeks and 1 more. Started Jan 2002; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00307814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307814.